Key Highlights

  • Inovio shares were up 195.48 percent to USD 1.78 in pre-market trading on November 2, 2026.
  • The FDA granted Accelerated Approval to VOCERYQ for adults with recurrent respiratory papillomatosis, announced October 30, 2026.
  • In the efficacy population, 7 of 26 patients, or 27 percent, needed no surgical papilloma removal over 12 months.
  • A court awarded the company an USD 80.4 million judgment against VGXI and GeneOne Life Science on October 20, 2026.
  • Cash was USD 36.7 million at June 30, 2026, excluding USD 18.3 million of net July offering proceeds.

What moved Inovio shares in pre-market trading

Inovio Pharmaceuticals (NASDAQ:INO) was up 195.48 percent to USD 1.78 in pre-market trading on November 2, 2026. The implied prior close is about USD 0.60 (calculated), so the stock is trading as a Penny Stock despite the surge.

The move follows a company announcement dated October 30, 2026, that the US Food and Drug Administration granted accelerated approval to VOCERYQ, its immunotherapy for adults with recurrent respiratory papillomatosis, known as RRP.

The approval in detail

According to the company, the product is used together with its CELLECTRA 5PSP delivery device and aims to reduce how often patients need surgery to remove airway papillomas. In the efficacy population, 7 of 26 patients, or 27 percent, had no surgical papilloma removal over 12 months.

The FDA requires a draft confirmatory study protocol by the end of 2026. The company said it expects shipping in about 60 days and a full commercial launch in the first quarter of 2027.

Business background and recent updates

Inovio is a biotechnology company developing DNA medicines that are delivered into cells with a handheld electroporation device. The RRP candidate, INO-3107, had an FDA decision date of October 30, 2026, according to the second quarter release.

For the second quarter of 2026, reported on August 12, 2026, the net loss narrowed to USD 6.0 million from USD 23.5 million a year earlier, helped by a USD 13.9 million non-cash Warrant gain.On October 20, 2026, the company said a court awarded it an USD 80.4 million judgment against VGXI and GeneOne Life Science, including USD 61.75 million in compensatory damages and USD 18.67 million in fees and costs. The company noted that the defendants' finances may impair collection.

Balance sheet and risks

Cash was USD 36.7 million at June 30, 2026, excluding USD 18.3 million of net proceeds from a July offering, and the company guided to a cash runway into the late first quarter of 2027. On July 29, 2026, it priced a USD 20.0 million public offering of 21,052,632 shares at USD 0.95 each with warrants exercisable at USD 1.10.

Penny stocks can be volatile and thinly traded, and a short runway raises the prospect of further dilution.

What to watch next

Investors will watch the first shipments expected in about 60 days, the commercial launch preparations for the first quarter of 2027 and the confirmatory study protocol due by the end of 2026. Collection of the court judgment and any new financing also matter.